MDxHealth SA MDXH.OQ MDXH.O is expected to show a rise in quarterly revenue when it reports results on February 26 for the period ending December 31 2024
The Herstal Liege-based company is expected to report a 20.4% increase in revenue to $23.36 million from $19.4 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for MDxHealth SA is for a loss of 19 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for MDxHealth SA is $6.00, above its last closing price of $1.86.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.28 | -0.27 | -0.40 | Missed | -48.1 |
Jun. 30 2024 | -0.27 | -0.26 | -0.42 | Missed | -58.5 |
Mar. 31 2024 | -0.31 | -0.30 | -0.31 | Missed | -3.3 |
Dec. 31 2023 | -0.22 | -0.11 | -0.39 | Missed | -254.5 |
Sep. 30 2023 | -0.21 | -0.19 | -0.40 | Missed | -108.3 |
Jun. 30 2023 | -0.25 | -0.22 | -0.30 | Missed | -37.6 |
Mar. 31 2023 | -0.32 | -0.32 | -0.50 | Missed | -55 |
Dec. 31 2022 | -0.67 | -0.65 | -1.10 | Missed | -68.4 |
This summary was machine generated February 24 at 21:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)